(e,z)-farnesol

(e,z)-farnesol is a lipid of Prenol Lipids (PR) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 3613 references associated with (e,z)-farnesol in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.

Here are additional resources we collected from PubChem and MeSH for (e,z)-farnesol

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,z)-farnesol

MeSH term MeSH ID Detail
Adenocarcinoma D000230 166 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Neoplasms D008175 171 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Osteosarcoma D012516 50 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Fibrosis D005355 23 associated lipids
Leukemia, Myeloid, Acute D015470 19 associated lipids
Hypergammaglobulinemia D006942 9 associated lipids
Glioblastoma D005909 27 associated lipids
Nephritis D009393 19 associated lipids
HIV Infections D015658 20 associated lipids
Neurilemmoma D009442 10 associated lipids
Per page 10 20 50 | Total 23

PubChem Biomolecular Interactions and Pathways

All references with (e,z)-farnesol

Download all related citations
Per page 10 20 50 100 | Total 813
Authors Title Published Journal PubMed Link
Cox AD et al. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation. 1994 J. Biol. Chem. pmid:8034681
Gibbs JB et al. Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo. 1993 J. Biol. Chem. pmid:8463291
Foster JM et al. Biosynthesis of isoprenoid compounds in Schistosoma mansoni. 1993 Mol. Biochem. Parasitol. pmid:8264731
Inoue H et al. Formation of farnesal and 3-hydroxy-2,3-dihydrofarnesal from farnesol by protoplasts of Botryococcus braunii. 1993 Biochem. Biophys. Res. Commun. pmid:8250896
Corsini A et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. 1993 Atherosclerosis pmid:8216498
Voziyan PA et al. Farnesol inhibits phosphatidylcholine biosynthesis in cultured cells by decreasing cholinephosphotransferase activity. 1993 Biochem. J. pmid:8240288
Touhara K and Prestwich GD Juvenile hormone epoxide hydrolase. Photoaffinity labeling, purification, and characterization from tobacco hornworm eggs. 1993 J. Biol. Chem. pmid:8396141
O'Donnell MP et al. Lovastatin inhibits proliferation of rat mesangial cells. 1993 J. Clin. Invest. pmid:8423236
Bradfute DL et al. Squalene synthase-deficient mutant of Chinese hamster ovary cells. 1992 J. Biol. Chem. pmid:1526971
Okazaki S et al. [A 13-week subcutaneous toxicity study of prednisolone farnesylate (PNF) in rats]. 1992 J Toxicol Sci pmid:1293320
Nagashima Y et al. [A 13-week percutaneous toxicity study of prednisolone farnesylate (PNF) gel in beagle dogs with a recovery period of 5 weeks]. 1992 J Toxicol Sci pmid:1293321
Nagashima Y et al. [A 52-week percutaneous toxicity study of prednisolone farnesylate (PNF) gel in beagle dogs with a recovery period of 8 weeks]. 1992 J Toxicol Sci pmid:1293322
Taniguchi H et al. [Reproductive and developmental toxicity study of prednisolone farnesylate (PNF)--study by subcutaneous administration of PNF prior to and in the early stages of pregnancy in rats]. 1992 J Toxicol Sci pmid:1293323
Taniguchi H et al. [Reproductive and developmental toxicity study of prednisolone farnesylate (PNF)--study by subcutaneous administration of PNF during the period of fetal organogenesis in rats]. 1992 J Toxicol Sci pmid:1293324
Aso S et al. [Reproductive and developmental toxicity study of prednisolone farnesylate (PNF)--teratogenicity study in rabbits by subcutaneous administration]. 1992 J Toxicol Sci pmid:1293325
Taniguchi H et al. [Reproductive and developmental toxicity study of prednisolone farnesylate (PNF)--study of subcutaneous administration of PNF during the perinatal and lactation periods in rats]. 1992 J Toxicol Sci pmid:1293326
Otsuka M et al. [Mutagenicity studies of prednisolone farnesylate (PNF)]. 1992 J Toxicol Sci pmid:1293327
Uchiyama H et al. [Effects of prednisolone farnesylate (PNF) gel on skin and ocular mucosa]. 1992 J Toxicol Sci pmid:1293328
Okazaki S et al. [A 13-week dermal toxicity study of prednisolone farnesylate (PNF) gel in rats with a recovery period of 5 weeks]. 1992 J Toxicol Sci pmid:1293330
Okazaki S et al. [A 52-week dermal toxicity study of prednisolone farnesylate (PNF) gel in rats with a recovery period of 8 weeks]. 1992 J Toxicol Sci pmid:1293331

Table of Content